

AGENDA

**Uniform Formulary Beneficiary Advisory Panel (BAP)
08 January 2020 @ 9:00 AM**

**Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004**

- **Administrative Meeting (BAP members report no later than 7:30 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4/Not Covered candidates.

The P&T Committee made recommendations for the following drugs/drug classes during the November 2019 meeting:

- **Drug Class Reviews**
 - *Phosphodiesterase-5 (PDE-5) Inhibitors*
 - *Insulins: Rapid-Acting Insulins (RAIs) Subclass*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *amlodipine oral suspension (Katerzia) – Calcium channel blocking agent in an oral suspension for hypertension*
 - *bremelanotide injection (Vyleesi) – Miscellaneous gynecological agent for Hypoactive Sexual Desire Disorder (HSDD)*
 - *darolutamide (Nubeqa) – Oral oncologic agent for non-metastatic castration-resistant prostate cancer (nmCRPC)*
 - *duloxetine extended-release (Drizalma Sprinkle) – Another formulation of duloxetine with similar indications to Cymbalta*
 - *entrectinib (Rozlytrek) – Oral oncologic agent for lung cancer*
 - *fedratinib (Inrebic) – Oral oncologic agent for myelofibrosis*

- *formoterol/aclidinium inhaler (Duaklir Pressair) – Pulmonary-2 Agent for Chronic Obstructive Pulmonary Disease (COPD)*
- *glucagon injection (Gvoke Hypopen and Prefilled Syringe [PFS]) – Binders-Chelators-Antidotes-Overdose Agent for severe hypoglycemia*
- *glucagon nasal spray (Baqsimi) – Binders-Chelators-Antidotes-Overdose Agent for severe hypoglycemia*
- *istradefylline (Nourianz) – Parkinson’s agent for off episodes*
- *lamivudine/tenofovir disoproxil fumarate (TDF) (Temixys) – Antiretroviral combination for human immunodeficiency virus (HIV)*
- *lefamulin (Xenleta) – Antibiotic for community acquired bacterial pneumonia (CABP)*
- *midazolam nasal spray (Nayzilam) – Anticonvulsants-antimania agent for seizures*
- *pexidartinib (Turalio) – Oral oncologic agent for tenosynovial giant cell tumors*
- *pitolisant (Wakix) – Sleep disorders: wakefulness promoting agent for narcolepsy*
- *segesterone acetate/ethinyl estradiol (Annovera) – Vaginal ring for contraception*
- *selinexor (Xpovio) – Oral oncologic agent for relapsing remitting multiple myeloma*
- *semaglutide oral tablet (Rybelsus) – Oral glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus in adults*
- *sumatriptan nasal spray (Tosymra) – Another formulation of sumatriptan*
- *tegaserod (Zelnorm) – Gastrointestinal-2 agent for constipation-predominant irritable bowel syndrome (IBS-C)*
- *tiopronin ER (Thiola EC) – Miscellaneous urinary agent for cystinuria*
- *upadacitinib (Rinvoq) – Targeted Immunomodulatory Biologic (TIB) for rheumatoid arthritis*

➤ **Utilization Management Issues**

➤ **Prior Authorization Criteria—New Criteria**

- *Skeletal muscle Relaxants and Combinations – chlorzoxazone 375 mg and 750 mg (Lorzone, generics)*
- *Anesthetic Agents: Local – lidocaine tetracaine 7%-7% topical cream (Pliaglis, generics)*
- *Parkinson’s Agents: rotigotine (Neupro) patch*
- *Oral Oncologic Agents: venetoclax (Venclexta) and idelalisib (Zydelig)*

➤ **Prior Authorization Criteria—Updated Criteria**

- *Pulmonary-1 Agents: combinations: budesonide/formoterol (Symbicort) AND mometasone/formoterol (Dulera)*
- *Targeted Immunomodulatory Biologics: certolizumab (Cimzia)*
- *Targeted Immunomodulatory Biologics: baricitinib (Olumiant, generics), tofacitinib (Xeljanz, Xeljanz XR), ixekizumab (Taltz), ustekinumab (Stelara)*
- *Oncological Agents: Prostate Cancer CYP-17 Inhibitors: abiraterone acetate (Zytiga, generics)*
- *Oncological Agents: Prostate Cancer 2nd Generation Antiandrogens: apalutamide (Erleada) and enzalutamide (Xtandi)*
- *Thrombopoietin Agents: Platelets: avatrombopag (Doptelet)*
- *Cardiovascular Agents: Miscellaneous: ivabradine (Corlanor)*
- *Hepatitis C Agents: Direct Acting Agents: ledipasvir/sofosbuvir (Harvoni) AND sofosbuvir (Sovaldi)*
- *Pulmonary-1 Agents: Idiopathic Pulmonary Fibrosis (IPF): pirfenidone (Esbriet) and nintedanib (Ofev)*
- *Oncological Agents: acalabrutinib (Calquence), duvelisib (Copiktra), ibrutinib (Imbruvica), larotrectinib (Vitrakvi), lenalidomide (Revlimid)*

➤ **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.